Ireland
--:--IST
Latest
Clinical Trials in Spain / NCT05894096
Active, not recruiting Not applicable

Air Cold Atmospheric Pressure Plasma Treatment for Acceleration of Venous Ulcer Healing

NCT05894096 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2023-03-24
Last updated
2025-01-03

Condition(s) studied

Venous Leg Ulcer

Investigational drug(s) / intervention(s)

Cold Atmospheric Plasma Jet TreatmentAlginate Patch

Cold Atmospheric Plasma Jet Treatment: Application of Colf Atmospheric Plasma Jet on the wound

Alginate Patch: Application of Alginate Patches on the wound

Study summary

In this medical trial, a novel prototype of a medical device based on a Cold Atmospheric Air Plasma Jet for the treatment is clinically tested on patients with venous leg ulcers. The device is characterized by producing the first cold air plasma jet compatible with living tissues at a low heat transfer rate with a temperature on the skin surface lower than 40 ºC. It has a practical design to be used by physicians during daily practice with a special focus on unhealed ulcers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Be of legal age (18 years). * Signed informed consent. * Presenting at least one venous ulcer larger than 1 cm2 that has not healed in the last 3 weeks from its appearance. * Absence of surgical indication for ulcer coverage by skin graft. Exclusion Criteria: * Uncontrolled diabetes mellitus (HbA1c \> 8%). If during the trial the patient suffers a decompensation of diabetes, it will be considered an adverse event. * Patient allergic to silver or any other material that will be used during the cure of the ulcer under study. * Concomitant treatment with vacuum-assisted closure (VAC) therapy. * Use of topical antibiotic therapy. The minimum washing time should be 48 hours. * Presence of critical limb ischemia defined as an ankle-brachial index (ABI) below 0.5 or a transcutaneous O2 pressure (TcPO2) below 15 mmHg. * Treatment with corticosteroids in the 14 days prior to the study or with other immunosuppressants. * Presence of a chronic or active skin disorder that may negatively influence wound healing (such as Marfan or Ehlers-Danlos syndrome, systemic lupus erythematosus, systemic sclerosis, or psoriasis). * Pregnancy or lactation. * Advanced or metastatic stage cancer. * Deficiency states. * Dementia. * Post radiation wounds. * Sepsis.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Hospital General La Mancha Centro Alcázar de San Juan Ciudad Real
Hospital General Universitario Gregorio Marañón Madrid Madrid
Clinica Universidad de Navarra Madrid Madrid
Hospital Clínico San Carlos Madrid Madrid
Clínica Universidad de Navarra Pamplona Navarre

More Clinica Universidad de Navarra, Universidad de Navarra trials in Spain

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05894096 on ClinicalTrials.gov ↗ ← All trials in Spain